Compounded Tirzepatide

Compounded tirzepatide is produced by 503A or 503B pharmacies when branded tirzepatide products are on the FDA drug shortage list or when compounding is determined to be medically necessary for a specific patient. Tirzepatide is a dual GIP and GLP-1 receptor agonist, which produces weight loss effects that are generally stronger than semaglutide alone based on clinical trial data. This makes it a compelling option for patients who have not achieved desired results on semaglutide or who are starting at higher BMIs.

For operators, compounded tirzepatide is often offered alongside compounded semaglutide as a higher-tier or escalation option. Pricing is typically higher than semaglutide, which supports better unit economics. Patient awareness of tirzepatide has grown significantly following the commercial success of Mounjaro and Zepbound, making patient education on compounded options more straightforward.

The regulatory landscape for compounded tirzepatide mirrors that of semaglutide - it is permitted when the branded product is on shortage and prohibited when it is removed. Operators should monitor FDA shortage designations and be prepared to adjust their formulary in response to regulatory changes.